Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report
Various immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis caused by atezolizumab plus chemotherapy in a patien...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364321001223 |
| _version_ | 1828127334170886144 |
|---|---|
| author | Yoshinari Endo, MD Yusuke Inoue, MD, PhD Masato Karayama, MD, PhD Yasuyuki Nagata, MD. PhD Hironao Hozumi, MD, PhD Yuzo Suzuki, MD, PhD Kazuki Furuhashi, MD, PhD Noriyuki Enomoto, MD, PhD Tomoyuki Fujisawa, MD, PhD Yutaro Nakamura, MD, PhD Naoki Inui, MD, PhD Takafumi Suda, MD, PhD |
| author_facet | Yoshinari Endo, MD Yusuke Inoue, MD, PhD Masato Karayama, MD, PhD Yasuyuki Nagata, MD. PhD Hironao Hozumi, MD, PhD Yuzo Suzuki, MD, PhD Kazuki Furuhashi, MD, PhD Noriyuki Enomoto, MD, PhD Tomoyuki Fujisawa, MD, PhD Yutaro Nakamura, MD, PhD Naoki Inui, MD, PhD Takafumi Suda, MD, PhD |
| author_sort | Yoshinari Endo, MD |
| collection | DOAJ |
| description | Various immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis caused by atezolizumab plus chemotherapy in a patient with lung adenocarcinoma and autoantibodies. Dramatic and lasting tumor regression in response to only one therapy cycle was achieved. Nevertheless, this case suggests that careful management is required when using immunotherapy in patients with autoantibodies. |
| first_indexed | 2024-04-11T15:48:49Z |
| format | Article |
| id | doaj.art-162234aaa6d9491fa55fa7295ccad67f |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-04-11T15:48:49Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-162234aaa6d9491fa55fa7295ccad67f2022-12-22T04:15:26ZengElsevierJTO Clinical and Research Reports2666-36432022-01-0131100263Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case ReportYoshinari Endo, MD0Yusuke Inoue, MD, PhD1Masato Karayama, MD, PhD2Yasuyuki Nagata, MD. PhD3Hironao Hozumi, MD, PhD4Yuzo Suzuki, MD, PhD5Kazuki Furuhashi, MD, PhD6Noriyuki Enomoto, MD, PhD7Tomoyuki Fujisawa, MD, PhD8Yutaro Nakamura, MD, PhD9Naoki Inui, MD, PhD10Takafumi Suda, MD, PhD11Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan; Corresponding author. Address for correspondence: Yusuke Inoue, MD, PhD, Second Division, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan.Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Oncology, Hamamatsu University School of Medicine, Hamamatsu, JapanThird Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, JapanSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanVarious immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis caused by atezolizumab plus chemotherapy in a patient with lung adenocarcinoma and autoantibodies. Dramatic and lasting tumor regression in response to only one therapy cycle was achieved. Nevertheless, this case suggests that careful management is required when using immunotherapy in patients with autoantibodies.http://www.sciencedirect.com/science/article/pii/S2666364321001223Immune checkpoint inhibitorsLung cancerAutoimmune hemolytic anemiaHemophagocytic lymphohistiocytosisCase report |
| spellingShingle | Yoshinari Endo, MD Yusuke Inoue, MD, PhD Masato Karayama, MD, PhD Yasuyuki Nagata, MD. PhD Hironao Hozumi, MD, PhD Yuzo Suzuki, MD, PhD Kazuki Furuhashi, MD, PhD Noriyuki Enomoto, MD, PhD Tomoyuki Fujisawa, MD, PhD Yutaro Nakamura, MD, PhD Naoki Inui, MD, PhD Takafumi Suda, MD, PhD Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report JTO Clinical and Research Reports Immune checkpoint inhibitors Lung cancer Autoimmune hemolytic anemia Hemophagocytic lymphohistiocytosis Case report |
| title | Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report |
| title_full | Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report |
| title_fullStr | Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report |
| title_full_unstemmed | Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report |
| title_short | Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report |
| title_sort | marked lasting disease regression and concomitantly induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in a patient with lung adenocarcinoma and autoantibodies receiving atezolizumab plus chemotherapy a case report |
| topic | Immune checkpoint inhibitors Lung cancer Autoimmune hemolytic anemia Hemophagocytic lymphohistiocytosis Case report |
| url | http://www.sciencedirect.com/science/article/pii/S2666364321001223 |
| work_keys_str_mv | AT yoshinariendomd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT yusukeinouemdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT masatokarayamamdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT yasuyukinagatamdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT hironaohozumimdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT yuzosuzukimdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT kazukifuruhashimdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT noriyukienomotomdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT tomoyukifujisawamdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT yutaronakamuramdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT naokiinuimdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport AT takafumisudamdphd markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport |